Tyra Biosciences (TYRA) Stock Forecast, Price Target & Predictions
TYRA Stock Forecast
Tyra Biosciences stock forecast is as follows: an average price target of $25.00 (represents a 21.42% upside from TYRA’s last price of $20.59) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
TYRA Price Target
The average price target for Tyra Biosciences (TYRA) is $25.00 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $33.00 to $17.00. This represents a potential 21.42% upside from TYRA's last price of $20.59.
TYRA Analyst Ratings
According to 4 Wall Street analysts, Tyra Biosciences's rating consensus is 'Buy'. The analyst rating breakdown for TYRA stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Tyra Biosciences Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 15, 2024 | Christopher Raymond | Raymond James | $33.00 | $21.57 | 52.99% | 60.27% |
| Aug 08, 2024 | Mitchell Kapoor | H.C. Wainwright | $25.00 | $19.50 | 28.21% | 21.42% |
| Mar 20, 2024 | Mitchell Kapoor | H.C. Wainwright | $23.00 | $17.37 | 32.41% | 11.70% |
| Feb 03, 2023 | - | Oppenheimer | $17.00 | $13.30 | 27.82% | -17.44% |
The latest Tyra Biosciences stock forecast, released on Aug 15, 2024 by Christopher Raymond from Raymond James, set a price target of $33.00, which represents a 52.99% increase from the stock price at the time of the forecast ($21.57), and a 60.27% increase from TYRA last price ($20.59).
Tyra Biosciences Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 2 | 2 | 3 |
| Avg Price Target | $29.00 | $29.00 | $27.00 |
| Last Closing Price | $20.59 | $20.59 | $20.59 |
| Upside/Downside | 40.85% | 40.85% | 31.13% |
In the current month, the average price target of Tyra Biosciences stock is $29.00, according to 2 Wall Street analysts offering twelve months forecast. The average price target represents a 40.85% increase as opposed to Tyra Biosciences's last price of $20.59. This month's average price target is down 0.00% compared to last quarter, and up 7.41% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 15, 2024 | Piper Sandler | - | Overweight | Initialise |
| Aug 08, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jul 08, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Jul 03, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| May 10, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Feb 03, 2023 | Oppenheimer | - | Outperform | Initialise |
Tyra Biosciences's last stock rating was published by Piper Sandler on Aug 15, 2024. The company Initialise its TYRA rating from "null" to "Overweight".
Tyra Biosciences Financial Forecast
Tyra Biosciences Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Tyra Biosciences's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. TYRA's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Tyra Biosciences EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
undefined analysts predict TYRA's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Tyra Biosciences's previous annual EBITDA (undefined) of $NaN.
Tyra Biosciences Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $-27.90M | $-25.54M | $-24.55M | $-25.45M | $-30.95M | $-28.60M | $-28.16M | $-26.11M | $-26.97M | $-23.38M | $-23.96M |
| High Forecast | $-27.90M | $-25.54M | $-24.55M | $-25.45M | $-30.95M | $-28.60M | $-28.16M | $-26.11M | $-26.97M | $-20.46M | $-23.96M |
| Low Forecast | $-27.90M | $-25.54M | $-24.55M | $-25.45M | $-30.95M | $-28.60M | $-28.16M | $-26.11M | $-26.97M | $-26.31M | $-23.96M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Tyra Biosciences's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. TYRA's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Tyra Biosciences SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Tyra Biosciences's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to TYRA last annual SG&A of $NaN (undefined).
Tyra Biosciences EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $-0.48 | $-0.44 | $-0.42 | $-0.43 | $-0.53 | $-0.49 | $-0.48 | $-0.45 | $-0.46 | $-0.40 | $-0.41 |
| High Forecast | $-0.48 | $-0.44 | $-0.42 | $-0.43 | $-0.53 | $-0.49 | $-0.48 | $-0.45 | $-0.46 | $-0.35 | $-0.41 |
| Low Forecast | $-0.48 | $-0.44 | $-0.42 | $-0.43 | $-0.53 | $-0.49 | $-0.48 | $-0.45 | $-0.46 | $-0.45 | $-0.41 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Tyra Biosciences's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to TYRA previous annual EPS of $NaN (undefined).
Tyra Biosciences Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| RAPT | RAPT Therapeutics | $1.83 | $42.20 | 2206.01% | Hold |
| PMVP | PMV Pharmaceuticals | $1.50 | $24.75 | 1550.00% | Buy |
| IPSC | Century Therapeutics | $1.46 | $20.00 | 1269.86% | Buy |
| XLO | Xilio Therapeutics | $0.81 | $7.00 | 764.20% | Buy |
| HOWL | Werewolf Therapeutics | $2.02 | $12.00 | 494.06% | Buy |
| MOLN | Molecular Partners | $5.51 | $29.00 | 426.32% | Buy |
| EWTX | Edgewise Therapeutics | $17.52 | $48.00 | 173.97% | Buy |
| MLYS | Mineralys Therapeutics | $11.23 | $30.00 | 167.14% | Buy |
| ERAS | Erasca | $2.86 | $7.00 | 144.76% | Buy |
| STOK | Stoke Therapeutics | $14.70 | $33.33 | 126.73% | Buy |
| CCCC | C4 Therapeutics | $5.40 | $11.33 | 109.81% | Hold |
| DSGN | Design Therapeutics | $4.67 | $9.67 | 107.07% | Buy |
| PHVS | Pharvaris | $19.12 | $38.50 | 101.36% | Buy |
| CGEM | Cullinan Oncology | $17.98 | $32.00 | 77.98% | Buy |
| TYRA | Tyra Biosciences | $20.59 | $25.00 | 21.42% | Buy |
| CNTB | Connect Biopharma | $1.25 | $1.50 | 20.00% | Buy |
| IKNA | Ikena Oncology | $1.69 | $1.33 | -21.30% | Buy |
| GRCL | Gracell Bio | $10.25 | $6.00 | -41.46% | Buy |
TYRA Forecast FAQ
Is Tyra Biosciences a good buy?
Yes, according to 4 Wall Street analysts, Tyra Biosciences (TYRA) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 100.00% of TYRA's total ratings.
What is TYRA's price target?
Tyra Biosciences (TYRA) average price target is $25 with a range of $17 to $33, implying a 21.42% from its last price of $20.59. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Tyra Biosciences stock go up soon?
According to Wall Street analysts' prediction for TYRA stock, the company can go up by 21.42% (from the last price of $20.59 to the average price target of $25), up by 60.27% based on the highest stock price target, and down by -17.44% based on the lowest stock price target.
Can Tyra Biosciences stock reach $30?
TYRA's highest twelve months analyst stock price target of $33 supports the claim that Tyra Biosciences can reach $30 in the near future.
What is Tyra Biosciences's current price target trend?
2 Wall Street analysts forecast a $29 price target for Tyra Biosciences (TYRA) this month, up 40.85% from its last price of $20.59. Compared to the last 3 and 12 months, the average price target increased by 40.85% and increased by 31.13%, respectively.
What are Tyra Biosciences's analysts' financial forecasts?
Tyra Biosciences's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-114M (high $-114M, low $-114M), average SG&A $0 (high $0, low $0), and average EPS is $-1.94 (high $-1.94, low $-1.94). TYRA's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-103M (high $-103M, low $-103M), average SG&A $0 (high $0, low $0), and average EPS is $-1.763 (high $-1.763, low $-1.763).